Hostname: page-component-7b9c58cd5d-v2ckm Total loading time: 0 Render date: 2025-03-15T18:44:47.265Z Has data issue: false hasContentIssue false

Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs

Published online by Cambridge University Press:  08 March 2006

Cem Uzun
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Muhsin Koten
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Mustafa Kemal Adali
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Faruk Yorulmaz
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Recep Yaǧiz
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Ahmet Rifat Karasalihoglu
Affiliation:
Department of Public Health, Trakya University, Faculty of Medicine, Edirne, Turkey
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The possible cochlear toxicity of systemically applied macrolides - erythromycin (ER), azithromycin (AZ) and clarithromycin(CL) - was investigated in guinea pigs by measuring transiently evoked otoacoustic emissions (TEOAEs). A single dose of 125 mg/kg intravenous (i.v.) ER caused no change in TEOAEs in guinea pigs (p>0.05), whereas AZ (45 mg/kg orally) and CL (75 mg/kg i.v.) reversibly reduced the emission response (p<0.05). The reversible reduction of TEOAE responses due to AZ and CL, which is in accordance with the clinical picture of AZ and CL ototoxicity, could likely be attributable to the transient dysfunction of outer hair cells. The present study reveals that at least one ototoxic effect of AZ and CL is on the inner ear. The results may also encourage planning clinical researches on TEOAE monitoring in patients receiving high doses of AZ or CL.

Type
Research Article
Copyright
© Royal Society of Medicine Press Limited 2001